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Abstract
Background: The global burden of disease is increasingly dominated by non-communicable diseases.These diseases are less
amenable to curative and preventative interventions than communicable disease. This presents a challenge to medical practice
and medical research, both of which are experiencing diminishing returns from increasing investment.
Objective: Our aim was to (1) review how medical knowledge is generated, and its limitations, (2) assess the potential for
emerging technologies and ideas to improve medical research, and (3) suggest solutions and recommendations to increase medical
research efficiency on non-communicable diseases.
Methods: We undertook an unsystematic review of peer-reviewed literature and technology websites.
Results: Our review generated the following conclusions and recommendations. (1) Medical knowledge continues to be generated
in a reductionist paradigm. This oversimplifies our models of disease, rendering them ineffective to sufficiently understand the
complex nature of non-communicable diseases. (2) Some of these failings may be overcome by adopting a “Systems Medicine”
paradigm, where the human body is modeled as a complex adaptive system. That is, a system with multiple components and
levels interacting in complex ways, wherein disease emerges from slow changes to the system set-up. Pursuing systems medicine
research will require larger datasets. (3) Increased data sharing between researchers, patients, and clinicians could provide this
unmet need for data. The recent emergence of electronic health care records (EHR) could potentially facilitate this in real-time
and at a global level. (4) Efforts should continue to aggregate anonymous EHR data into large interoperable data silos and release
this to researchers. However, international collaboration, data linkage, and obtaining additional information from patients will
remain challenging. (5) Efforts should also continue towards “Medicine 2.0”. Patients should be given access to their personal
EHR data. Subsequently, online communities can give researchers the opportunity to ask patients for direct access to the patient’s
EHR data and request additional study-specific information. However, selection bias towards patients who use Web 2.0 technology
may be difficult to overcome.
Conclusions: Systems medicine, when combined with large-scale data sharing, has the potential to raise our understanding of
non-communicable diseases, foster personalized medicine, and make substantial progress towards halting, curing, and preventing
non-communicable diseases. Large-scale data amalgamation remains a core challenge and needs to be supported. A synthesis of
“Medicine 2.0” and “Systems Science” concepts into “Systems Medicine 2.0” could take decades to materialize but holds much
promise.
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Current Limitations in the Study and
Management of Chronic Disease
Medical science has brought clear and dramatic improvements
to health over the past 150 years. This has included effective
cures and preventions as well as important public health
measures. As a consequence of many of these advancements,
the leading causes of death and disability have shifted from
infectious diseases to more complex non-communicable
diseases. In the past 50 years, expenditure on health research
and health care has increased dramatically to meet the new
challenges that treating and preventing these multifaceted
diseases presents. However, combating chronic disease has
proven significantly more difficult and costly than infectious
disease, with it becoming increasingly difficult to continue
raising life expectancy and healthy life expectancy [1]. Many
spheres of academia and clinical practice have shifted away
from an intent to cure, to an attempt to slow down pathological
processes and prevent complications. This is in part due to the
inability of science to determine which individuals will suffer
the most from any given risk factor, or who will benefit most
from specific interventions.
Current medical science is largely conducted using the
reductionist paradigm, which assumes that complex entities are
best understood by breaking them down into smaller, simpler
components. Detailed analysis of the weaknesses of this
assumption has been done elsewhere [2], but principally,
reductionism limits our ability to understand how multiple
variables interact with one another to create emergent effects.
The reductionist approach does offer a useful first step for the
understanding of a complex system because it helps identify
key components. However, a strong and enduring emphasis on
the reductionist approach risks over-simplification (focusing
only on a handful of major factors with the biggest effect, while
the sum of minor factors may be considerable) and
generalization (assuming that a common cause-effect
relationship applies equally in all cases). Moreover, an excessive
focus on a limited number of pathways may impede our ability
to understand both the behavior of the system as a whole, as
well as system variability between individuals. Our etiological
models of seemingly disparate chronic diseases include a
striking number of common pathways. For example, alterations
of the tumor necrosis factor alpha (TNF-alpha) gene have been
implicated in 88 clinically distinct diseases [3]. However, it
remains unclear under what circumstances increased TNF-alpha
levels cause an individual to develop rheumatoid arthritis,
atherosclerosis, or a septic cytokine cascade. It is assumed that
many such pathways interact to produce disease outcomes.
Rarely can we adequately describe why a disease develops in
an individual, their prognosis, the effect of risk factor
modification on an individual, or the likelihood of family being
affected by a similar disease.
The type of drugs dispensed to patients further reflects our
limited understanding of the true cause of disease. While some
drugs can reverse the original disease process to provide a near
cure (eg, antibiotics, chemotherapy), many more provide only
temporary relief to the current physiological imbalance and fail
to cure (eg, thyroxin, antidepressants, anticonvulsants, steroids,
diuretics). Others still simply dampen the body’s capacities to
exacerbate the condition in a symptomatic or palliative [4]
fashion (eg, beta blockers, warfarin) with significant side effects.
Another weakness in our management of chronic diseases stems
from the way research studies and clinical guidelines consider
each disease in isolation, while in reality most patients have at
least one comorbidity. This leaves patients with an expanding
burden of treatment, polypharmacy, increased side effects,
unintended drug interactions, and reduced adherence.
This pattern of diminishing returns necessitates a reevaluation
of the approach that medical science has taken in the study and
management of chronic diseases. As chronic diseases are
substantially more complex than infectious diseases, additional
approaches are probably required to overcome the limitations
of reductionism. In this essay, we aim to (1) document medical
science’s first steps in moving away from reductionism towards
more complex models, (2) assess the potential benefit of
introducing Systems Science into medical science and evaluate
the relative strengths and weaknesses of various technologies
in facilitating this (such as Medicine 2.0), and (3) present our
suggestions of how to best increase medical research efficiency.
To achieve this, we combine an unsystematic review of
peer-reviewed literature, with a review of two websites known
for the dissemination of novel technologies and ideas (Wired,
TED). We then try to bring together these disparate lines of
thought, across a range of disciplines and industries, into a
subjective but hopefully thought provoking synthesis.
Supplementing the Reductionist Paradigm
Should the prevalent theoretical model, framework, or paradigm
find it increasingly difficult to account for experimental data,
alternatives to the prevalent model should be considered [5].
This can be done by replacing the old model or by adding
supplements to the existing model [6]. We argue that three such
supplements have recently been added to the core of
reductionism. First, select chemotherapy agents were found to
work particularly well for subtypes of breast cancers and
leukemia, which corresponded to genetic subtypes of the disease.
This reveals that diseases may look similar on the outside but
can function very differently on the inside. As our knowledge
of this etiome [3] (the precise etiological pathways by which
genetic and environmental agents cause a disease) grows, it
becomes useful to name each diagnostic subcategory with
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appropriate subdivisions. The term “intermediate
pathophenotype” [7] has been suggested to capture these
subdivisions. Linguistically, this denotes a focus on end-state
pathology, the likely object of interest for pathologists and
systems biologists. Clinicians, epidemiologists, and biomedical
scientists are, however, more interested in upstream etiology
and the narration of an individual’s past and likely future.
Perhaps adopting the term “etiphenotype” instead would make
Systems Medicine more accessible to clinicians (or alternatively,
letting the term “etignosis” complement “diagnosis”).
The second supplement to reductionism came from the
observation that most patients have more than one disease at
any given time and that some diseases tend to cluster together.
For example, people with diabetes have a greater risk of
developing certain other diseases, such as stroke. Recent
evidence has identified numerous early commonalities, such as
“the metabolic syndrome” or “diabesity”, but our scientific
language and modes of thought struggle to describe the
interconnectedness of these tightly intertwined etiological
processes [8]. Reductionism is ill-suited to deal with the question
of comorbidity, prompting a search for alternative models [9].
Third, in many cases it appears better to treat complex diseases
with a cocktail of drugs administered simultaneously. This has
been applied in the treatment of infections (eg, tuberculosis and
human immunodeficiency virus), as well as for chronic
conditions (eg, acute coronary syndrome, exacerbations of
chronic obstructive pulmonary disease) [10]. Advances in such
complex, combined interventions have prompted the Medical
Research Council to issue guidance on how they should be
monitored and evaluated [11]. We believe that this will give
only modest improvements, as intervention development will
still remain somewhat blind and ignorant of the intricacies of
etiological processes.
Modifying the Reductionist Paradigm With
Network Medicine
A transitionary model of medical research is emerging that
attempts to reconcile some of the discrepancies outlined above.
There is much hope that network medicine could be better suited
to understand the basic biological processes that culminate in
health and disease [12,13]. This framework suggests that
complex diseases are the emergent result of perturbations in
multiple genes that are interconnected to one another to create
a disease module (Figure 1). A hypothetical study of diabetes
could begin by mapping the system of proteins that are
responsible for healthy function like glucose regulation (Figure
1, panel a), also known as the interactome of proteins. Next,
existing literature is used to identify a candidate gene or protein
critical in etiology (Figure 1, panel b). This protein is mapped
onto the interactome to identify a smaller set of proteins that
directly influence the candidate protein (Figure 1, panel c), to
identify a suspected diabetes disease module (colored red).
Concurrent mapping of comorbid diseases (such as stroke in
blue) can identify structural reasons for comorbidity as well as
common premorbid states (such as the metabolic syndrome,
marked by the red-blue proteins). Models like this can account
for the effectiveness of combined interventions (Figure 1, panel
d, dark blue proteins) and identify novel drug targets (Figure 1,
panel d, light blue). Such models have been used to identify
novel genes across a range of cancers [14-16]. It has also
allowed drugs to be re-positioned for other diseases, such as
using the anti-ulcer drug cimetidine in the treatment of lung
cancer [17].
Figure 1. The methodological steps by which network medicine identifies disease modules and predicts novel protein targets for intervention.
We believe that the network medicine approach can achieve
half the paradigm shift required toward systems medicine.
However, such models remain incomplete because of the
following weaknesses [18]. (1) When considering disease,
network medicine looks only at snapshots of end-stage illness.
The model cannot be applied to longitudinal data to describe
the gradual shift that takes place when healthy states slowly
transform into diseased states. This weakness stems from the
model’s implicit assumption that disease processes (such as
glucose dysregulation) are merely broken flipsides of healthy
processes (glucose regulation). The cascade of events that caused
the shift from healthy state to diseased state are irrelevant and
not investigated [19]. (2) Network medicine focuses exclusively
on the intracellular level of proteins and genes. Researchers
interested in higher order risk factors (such as how weight gain
is influenced by childhood nutrition, family upbringing,
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socioeconomic status, or the physical environment of green
spaces and fast food outlets) struggle to utilize network medicine
models [20]. (3) Simplistic causal modeling, wherein diseased
genes and proteins are thought to exert their effects uniformly
across a range of interindividual and interenvironmental
variation. Thus network medicine struggles to model how
genetic risk interacts with environmental risk to create disease.
We feel that these three weaknesses will keep our models of
disease largely incomplete, thus perpetuating many of the
shortcomings outlined in our introduction.
Replacing the Reductionist Paradigm
With Systems Medicine
It helps to begin by clarifying our core terms. A System can be
defined as a set of components that are related to one another
in a meaningful way (centerpiece, Figure 2). Systems Science
is the formal study of systems [21]. Systems Thinking describes
modes of thought that focus on the connectedness and
interrelationships of components, rather than focusing on the
components themselves. Systems Theory is a set of theories that
try to derive generalizable organizing principles that apply to
all systems. For example, complex systems can maintain robust
performance during external perturbations, thanks to
system-wide properties such as modularity and built-in
redundancy (ie, having two kidneys), features that are seen in
biological and non-biological systems alike [19]. Systems
Biology is the study of how biological functions emerge from
the interactions between the components of living systems and
how these emergent properties in turn influence the behavior
of lower-level components [22]. The field developed quickly
during the past decade, due to technological advances in
generating large amounts of high-throughput data very quickly,
along with the interdisciplinary ability to compute, model, and
make sense of this data.
Figure 2. Schematic illustration of the core differences between reductionism and systems science, when analyzing the properties of a system.
To date, little of the above paradigms have been incorporated
into medical research. In part, this may be due to difficulties in
amalgamating large-scale clinical datasets. However, as such
technical barriers begin to fall away, increasing attribution can
be placed on lack of knowledge about Systems Science among
the medical research community. Indeed, those looking for a
working definition of Systems Medicine may be baffled by the
diversity of opinions out there [19,23,24]. Historically, Systems
Medicine has been defined as the clinical application of Systems
Biology approaches to medicine, where traditional model-driven
experiments are informed by data-driven models in an iterative
manner [25]. We see Systems Medicine as the long-term
objective of a wider paradigm shift in medical science, at the
end of which a range of different models and approaches will
coexist under the Systems Medicine umbrella. All of these
models will be substantially more complex than the models
used in Reductionism or Network Medicine. We suggest that
Systems Medicine models should include two or more of the
following organizing principles of the human body:
non-linearity, multi-agency, multi-levelness, or adaptivity [26].
J Med Internet Res 2015 | vol. 17 | iss. 3 | e64 | p.4http://www.jmir.org/2015/3/e64/
(page number not for citation purposes)
Tillmann et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
Non-linearity means that the independent variables interact with
one another and modify each other’s effects on the dependent
variable. This makes the dependent variable exhibit emergent
properties that can be understood only when all of the
independent variables are assessed concurrently. Such
interactions have been documented between behavioral risk
factors, between two genes [27], between transcribed mRNA
and regulatory microRNA [28], between single nucleotide
polymorphisms (SNP) and expression quantitative trait loci
[29], as well as between transcription factors [30]. Perhaps most
important of all are gene-environment interactions, which have
begun to emerge for obesity [31], coronary artery disease [32],
asthma [33], colorectal cancer [34], depression [35], eczema
[36], Alzheimer’s disease [37], and multiple sclerosis [38] to
name a few. Models of systems medicine need to be built and
empirical data assembled so that the detection of interactive
effects and non-linear dynamics is facilitated. Contrast this with
the stance taken in most introductory epidemiology and medical
statistics courses, where interactive effects are seen as
“nuisance” phenomena and students are discouraged against
opening such cans of worms because of seemingly
unmanageable type 1 errors. Regrettably, the study of interaction
phenomena remains a niche field. This stifles progress at
understanding any non-linear mechanisms of the human body.
Non-linearity can be present in relatively simple systems [39].
Consider the example of a system where smoking and drinking
alcohol leads to increased stroke risk, through the upregulation
of a hypothetical inflammatory cytokine called “smokdrink”.
These two risk factors can interact with one another and produce
non-linear responses that are quite complex in nature (such as
a dramatic increase in smokdrink, but only if you drink more
than 3 units a day and have accumulated more than 20 years of
smoking damage). Nonetheless, our model remains simply
non-linear (Multimedia Appendix 1, frame 1). Next, we can
expand the model to account for how stroke is further influenced
by another non-linear system, namely the cholesterol system
(frame 2). If we view smokdrink and cholesterol as our two
agents of stroke, then we have built a multi-agent model (frame
3). This concept is useful to bear in mind as the outcome of
complex systems is rarely determined by one agent, but rather
is the interaction between multiple agents (Multimedia Appendix
1, red arrows at the top of frame 3). Many of these agents remain
directly unmeasurable, but their parameters can be estimated.
For example, even before we discover the inflammatory cytokine
smokdrink, we can calculate that 20 cigarettes + 3 pints a day
has a similar effect on stroke, as does 10 cigarettes + 5 pints a
day. Constructing intermediary agents in silico (such as
smokdrink and cholesterol) facilitates our conceptual and
mathematical understanding of the nature of dynamic disease
processes. Such constructs could also include the inflammatome
[40], the Metabolic Syndrome scale, the
Hypothalamus-Pituitary-Axis dysregulation scale, or the
allostatic load scale [41].
Multi-level models account for how people often form natural
groups, which in turn influence individual behavior and disease
outcomes. A grouping variable, such as “living in a deprived
neighborhood or not”, can exert its effect on the disease outcome
directly just like any other risk factor (Multimedia Appendix 1,
frame 4, dotted blue line), or indirectly by modifying the effect
of a lower order risk factor (such as drinking alcohol;
Multimedia Appendix 1, red dotted lines). Although it may be
tempting to enter “living in a deprived neighborhood” into the
model alongside the other variables, this violates certain
statistical assumptions. Accordingly, models known
interchangeably as nested, hierarchical, or multiscale models,
are useful to take account of the multi-levelness of such real-life
phenomena.
Finally, all the models presented so far compare states of full
health against states of full illness. The sequence of events over
which full health deteriorates towards full illness remains
unknown. To understand this process, we must build dynamic
models of the human body. The core principle here is adaptivity,
wherein after a certain stimulus, the system modifies its own
response pattern in anticipation of similar stimuli in the future.
It is through processes such as down-regulation, long-term
potentiation, habituation, and synaptic learning, that the body
modifies its definitions of “an ideal state” or “an ideal response”.
Thus the rules that explain the behavior of homeostatic systems
are nested in larger systems, called homeodynamic systems
[41]. Imagine an individual whose homeostatic system is trying
to keep its blood glucose level around 6, and Body Mass Index
(BMI) around 22 (also known as an attractor zone). The system
tolerates and shows resilience in the face of a range of
perturbations in the short-term (such as skipping a meal, met
by glycogenolysis), medium-term (entering Ramadan, met by
lipolysis), or permanent (increased energy demands, met by
increasing appetite). Whatever happens, the system will try to
return to the initial attractor zone. This is easy to do if the
person’s state meanders only slightly in the immediate phase
space around the central attractor zone, also known as the
system’s basin (eg, glucose 4-8, BMI 20-24). However, if the
person’s state moves far away enough from the basin (eg,
glucose 2, BMI 10), the integrity of the system is at stake and
death from starvation may follow. In other diseases, the attractor
zone may shift to BMI 26 (diagnosed as overweight) or to
glucose 12 (diagnosed with diabetes) over a few decades. Other
diseases still may show less gradual but more sudden shifts with
bifurcation into a far away attractor zone (as seen in an acute
epileptic seizure [42], many other acute presentations, but also
in agent-based models of community interventions [43]). Other
diseases can show cyclical flip-flop behavior between two
attractor zones (such as is seen in bipolar disorder [44]).
Dynamical Systems Theory focuses on understanding how and
why these attractor zones change over time. Chaos Theory
describes a type of system change that is particularly sensitive
to initial conditions (such as seen in the Barker and Hygiene
hypotheses). Similar models have been used to understand cell
fates [45], endothelial function [46], cytokine function [47],
heart rate variability [48], atrial fibrillation [49], septic shock
[50], and multiple organ dysfunction syndrome [51].
Understanding these dynamic processes may lead to targeted
interventions of preventative [52] or curative nature. For
example, animal models suggest that infection with helmliths
can reprogram autoimmune disease states towards healthier
ones in colitis [53], gastric atrophy [54], multiple sclerosis [55],
and diabetes [56].
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Analytical Approaches to Systems
Medicine
Conducting systems medicine research will require numerous
changes to how medical scientists and epidemiologists conduct
their daily work. Such changes have been poorly addressed in
the existing literature. Fundamentally, an entire new approach
to data collection and analyses is required. If most risk factors
interact with one another to create small interactive effects,
many of which are nested in intricate multi-levels of hierarchy,
then the detection of such intricacies will require large numbers
of patients with large numbers of variables [57].
Once assembled, such high-fidelity datasets could be explored
for “hot spots”, or loci of association, between risk factor data
(including behavioral, environmental, and sociological risks),
molecular data (including genomic, trascriptomic, and proteomic
data), and clinical outcomes, in order to identify and treat
etiphenotypical subgroups. Some of this exploration will take
the narrow shape of testing a priori hypotheses. Other
exploration will use high-throughput techniques to scan more
broadly and identify novel hypotheses for subsequent scrutiny
[58,59]. This may be facilitated by machine learning algorithms
[60]. For example, the world’s most advanced supercomputer,
IBM Watson, has recently been given access to data on over a
million cancer patients, as well as the emerging oncological
literature. It is hoped that Watson will support and enhance
clinical decision making in real time [61]. This may shatter the
traditional view of humans generating hypotheses on which
computers calculate the test statistic, as computers like Watson
may also become indispensible in hypothesis generation. Our
vision of Systems Medicine becomes impossible without
seamless collaboration with mathematicians, modelers, and data
scientists, so that the right modeling tools can be used and
combined to appropriately balance sufficient complexity with
practical utility.
A Roadmap to Systems Medicine
Although multiple challenges impede the integration of systems
approaches within medical research, we prioritize five that
deserve attention first. (1) Existing models that view the human
body as complex adaptive systems are limited and need
specialist development. Our review of the literature suggests
that while textbooks exist on modeling for Systems Science and
Systems Biology, little consensus exists on modeling for
Systems Medicine. (2) While large-scale research projects (such
as the Human Genome Project, Wellcome Trust Case Control
Consortium, Virtual Physiological Human, ECell, Cancer
Genome Atlas, Human Brain Project) are developing at a
promising rate, the majority of research continues to be
conducted in an almost proprietary-like mindset of non-sharing,
with individual teams collecting and holding data in small silos.
This makes it difficult to create the large datasets required for
systems analysis. (3) While some organizations (like IBM, Sage
Bionetworks, and Farr Institute) can foster multidisciplinary
teams between medical researchers and information specialists,
this collaboration gap remains large in most areas of public
research. (4) Although research funders are beginning to
recognize and invest in long-term and larger research endeavors,
particularly in database curation, the vast majority of funds
continue to be spent on low-complexity projects with short-term
deliverables and seemingly low risk. Many such projects are
underpowered in breadth, depth, and complexity to sufficiently
address the problems they seek to address, with sometimes
negligible subsequent improvement in our knowledge base. (5)
The obstacles above will yield with sufficient energy and
leadership; however, progress at each front continues to be slow
due to the prevalent reductionist culture in the medical research
community and general risk aversion to engage with new
technology (particularly those that may alter existing power
relations). Therefore, greater discussion, awareness, and
education of differences between systems medicine and
reductionism are required across the board, in order to promote
and facilitate interest and activity in this important transition.
Sharing Data
The medical research community itself is a complex adaptive
system. Shifting this toward a more efficient, systems-science
configuration will require time and effort to be applied at
multiple levels. We believe that the second obstacle mentioned
above, creating large datasets, is most pressing so we discuss
this in detail. There are two possible non-competing solutions:
(1) sharing data between researchers or (2) using data from
electronic health records (EHR) for research purposes. Although
data sharing appears to be increasing, most research data are
not shared or recycled outside the original project team. A range
of factors discourage data sharing. Project-specific data are
often collected using context-specific priorities, definitions, and
measurement tools that are rarely compatible with other
peer-researchers, let alone researchers looking at the picture
from a higher or lower level of order [62]. Data access requests
are often cumbersome and slow, and some researchers may be
wary of giving up their competitive edge [63]. Ultimately, even
if all research groups pool their data successfully, a rich trove
of clinical process and outcome data will continue to be held
by health care providers who are not involved in research.
Health care data are never assembled for research purposes,
which substantially hampers its transferability. For example,
patients with borderline disease states are often “upcoded” into
more severe disease states, as this brings financial rewards to
the health care provider. Some EHR data may always be absent
or of insufficient quality to be useful in medical research (eg,
tracking the daily improvement of inpatients with cellulitis or
fluid overload, which is difficult to quantify). However, other
EHR data lend themselves very well to scientific analyses,
particularly as drug prescription data are of exceptional quality.
Furthermore, as health care is carried out on real patients,
studying the real-life effects of drugs is preferable to
unrepresentative clinical trials, particularly in understanding
how one drug can accidentally influence two disparate diseases
[64,65]. Future work could clarify which health care data are
transferrable to medical research, and develop some tools to
facilitate this. For example, should some severe diagnoses, when
seen in conjunction with other hospital laboratory parameters,
be downcoded back to a more truthful level, to correct for
financial upcoding in EHR? The integration of health care and
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research data will create its own technical, logistical, and legal
challenges, and at present we cannot tell if this will be
worthwhile. If attempted, we suggest that groups of patients
could be subdivided empirically based on their differential risk
factor profiles, disease trajectories, or molecular data [66], and
these subgroups subsequently explored in more detail for
evidence of etiphenotypical subgroups.
Unlocking Health Care Data
There is growing support for the collation of EHRs for
secondary research purposes [67]. Transmission of data is
typically thought to proceed with researchers asking health care
providers for access to anonymized data [68]. Added value can
be gained by integrating data from multiple providers [69].
Overall, this approach offers substantial productivity gains.
However, this benefit must be considered against the drawback
of reduced data accuracy.
As an alternative, we suggest an approach where researchers
ask patients directly for their data, who in turn have to ask
hospitals for their data. The advantage here is that routine
medical data could be augmented by study-specific scientific
tests (such as genotyping). The disadvantage is that samples
will not be representative of the wider patient group, but biased
towards those comfortable with sharing their personal data with
scientists over the Internet, a concept that probably frightens
most patients today. It also requires EHRs to be personally
accessible and personally controlled—a feature that is still under
development [70], but with some proof of concept from private
settings [71].
Online Communities
Web 2.0 technology is creating a social Web, where users create
content, share useful information with interested peers, and
moderate each other’s activities (eg, Facebook, eBay,
ReseacherGate) [72]. Web 2.0 has been combined with the
power of crowdsourcing (the force behind projects like
Wikipedia) to foster Science 2.0 (also known as Open Science
or Cyberscience 2.0) [73]. Here, online platforms facilitate
large-scale data sharing between researchers who can merge or
re-analyze each other’s data (eg, HapMap project, Sage
Bionetworks). Some of these projects (eg, GalaxyZoo) are also
enlisting the power of citizens in the scientific endeavor. A
seminal article by Eysenbach in 2008 [74] detailed how the
application of these Web 2.0 technologies to personally
controlled health care records will create “Medicine 2.0”. This
will be a world where the collaboration gap between researcher,
clinician, and patient will narrow. Online patient communities
such as PatientsLikeMe are not only useful to facilitate peer
transfer of knowledge [75] but also in scientifically testing new
drug applications [76].
To the best of our knowledge, a major gap in the current
literature is the fact that systems medicine researchers have
never suggested that their vision could be achieved quicker
using Medicine 2.0 tools. Similarly, although Medicine 2.0
enthusiasts have begun to associate their ideas to Big Data, Web
Science, Health Web Science, and the Semantic Web [77], none
have spoken of the potential for Medicine 2.0 to further our
understanding of the human body as a complex adaptive system.
We urge these two important communities to begin collaboration
on what we suggest could be called “Systems Medicine 2.0”
(Figure 3). Understandably, few patients will trust their most
sensitive secrets with an amorphous, faceless research
community. An online community with detailed researcher
profiles, faces, and credentials (eg, ReseacherGate) could be
augmented by allowing participants and researchers to interact
with one another. Reliable feedback systems (such as those seen
in Amazon and eBay) will be central to creating sufficient trust.
To date, most sites have focused on fostering
researcher-researcher collaboration [78,79], or patient-patient
collaboration. The next step would be to foster bi- or
tri-directional links (also to clinicians), with the added challenge
of increased knowledge asymmetries.
Another challenge for Systems Medicine 2.0 is how health care
data has very poor interoperability, both nationally and
internationally. We welcome the work of the Joint Initiative on
SDO Global Health Informatics Standardization to facilitate
the rapid adoption of common health informatics standards. A
related challenge is how various Systems Medicine research
teams will initially create their own datasets, analytical
programs, and models. Reporting these via traditional journals
will hamper progress. Datasets, programs, and models should
be shared, scrutinized, and developed, perhaps by making use
of the efficiency tools perfected by the Open Source movement
[80]. Open access [81], open standards, open source software
[82], and open competitions [83] can foster faster innovation
and drive efficiency. Ideally, the entire Systems Medicine
community could see themselves as working on the same
project, akin to the global communities who brought us Linux,
Mozilla Firefox, Wikipedia, HUGO, and Systems Biology.
To start the discussion of how the research community can move
towards Systems Medicine, we have compiled a list of
suggestions (Textbox 1). This is neither exhaustive nor
comprehensive and is designed merely to stimulate discussion,
development, and implementation of Systems Medicine.
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Textbox 1. Initial suggestions for the advancement of systems medicine.
Governments and key research funders:
• training systems scientists, big data engineers, and medical researchers
• incentivizing and normalizing multidisciplinary collaboration for systems medicine
• incentivizing and normalizing the sharing of laboratory data as well as health care data
• earmarking research funds for systems medicine
• national leadership on systems medicine strategy and implementation
Legislation for the Web 2.0 era:
• EHRs to be recognized as patient property
• EHR systems must facilitate the simple and free export/import of data by abiding to global standards and/or open standards
• anonymized research on EHRs is permitted and automatically facilitated, unless patients opt out
• define if and how data can be accessed for commercial purposes and how any proceeds are divided
Scientific community:
• opinion leaders to promote the benefits of Systems Science approaches in medicine
• disease-specific expert bodies (eg, colleges) to facilitate common standards of data collection in their fields
• early Systems Medicine 2.0 academics to focus their papers at one flagship journal (eg, Journal of Medical Internet Research)
Software developers:
• develop an online community that links together systems scientists and modelers, big data engineers, medical researchers, and subsequently
patients
International co-ordination:
• international leadership and co-ordination (eg, World Health Organization) to promote all of the above
• an online data-sharing directory listing all large datasets pertaining to Systems Medicine
Figure 3. The historical origins of “Systems Science” and “Medicine 2.0”, and the potential for their combination into “Systems Medicine 2.0”.
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The prevalent paradigm in medical science is reductionism,
whose limitations have become increasingly apparent, resulting
in diminishing returns. This paradigm has been supplemented
and modified with the framework of network medicine. If further
developed with Systems Science approaches, this has the
potential to evolve into fully fledged Systems Medicine
paradigm. This neatly complements advances in
Internet-powered medicine (Medicine 2.0), but as yet the two
fields have yet to take advantage of each other’s nascent
existence. We hope that our paper can bridge this conceptual
gap and advance mutual interest and collaboration between
these two, to foster Systems Medicine 2.0. This could lead to
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